INVESTORS
We operate with trust and do the right thing
News
-
SEP 28 2020NewsNew combo therapy will make up for unmet needs of Tagrisso in NSCLC patients...the median progression-free survival (PFS) of the third- generation TKI osimertinib was only about 18 months, and it was shorter in Asians. There are unmet needs in this area, and the combination of lazertinib and amivantamab will improve PFS with good tolerability
-
DEC 12 2019NewsYuhan to start phase-3 trial on lung cancer drug LazertinibYuhan Corp. said it would start a phase-3 global study to evaluate the efficacy of Lazertinib (YH25448) as the first-line treatment for non-small cell lung cancer (NSCLC)
-
JUN 3 2019NewsY-biologics, Genosco ink deal for cancer immunotherapy combosY-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development
-
NOV 5 2018NewsYuhan signs $1.25b licensing deal with JanssenSouth Korean pharmaceutical giant Yuhan announced Monday that it had licensed out its new clinical-stage lung cancer drug to Janssen Biotech in a deal potentially valued at up to $1.25 billion
